Legal Proceedings
−Removed: From time to time, we may be involved in various legal proceedings arising from the normal course of business activities.
−Removed: Defending such proceedings is costly and can impose a significant burden on management and employees.
+Added: On May 6, 2024, a class action complaint was filed in federal district court in the District of Maryland, Southern Division, naming as defendants, the Company and three of the Company’s current executive officers, captioned Mogan v.
+Added: Altimmune, Inc.
+Added: , et al., No.
+Added: 24-cv-01315 (D.
+Added: The complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of material fact to the investing public including the plaintiff and class members, who purchased or otherwise acquired the Company’s common stock between December 1, 2023 and April 26, 2024.
+Added: The plaintiff and class members seek to have the action maintained as a class action under Rule 23 of the Federal Rules of Civil Procedure
+Added: and for the defendants to pay damages, interest, and an award of costs, including attorneys’ fees.
+Added: The Company intends to vigorously defend against the lawsuit.
+Added: From time to time, we may be involved in various legal proceedings or investigations, which could be costly and impose a significant burden on management and employees.
The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.
−Removed: There have been no material changes from the risk factors disclosed in our Annual Report on Form 10-K filed with the SEC on February 28, 2023.
+Added: There have been no material changes from the risk factors disclosed in our Annual Report on Form 10-K filed with the SEC on March 27, 2024.
Unregistered Sales of Equity Securities and Use of Proceeds
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.